Form 4: Esperion CFO Sells Shares for Tax Obligations

Esperion Therapeutics CFO Benjamin Halladay sold 7,046 shares of common stock at $2.808 per share to cover tax obligations on vested restricted stock units.

Summary

• Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics, Inc., reported a sale of common stock.
• On September 17, 2025, Halladay disposed of 7,046 shares of Esperion Therapeutics common stock.
• The shares were sold at a price of $2.808 per share.
• The purpose of the sale was to satisfy tax obligations related to vested restricted stock units.
• Following this transaction, Halladay directly beneficially owns 474,862 shares of common stock.
• This beneficial ownership includes 7,446 shares recently acquired through Esperion's Employee Stock Purchase Plan.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale to cover tax obligations on vested equity, which is a neutral event. The acquisition of shares via ESPP is a minor positive, balancing the sale.

Positives

• The reporting person recently acquired 7,446 shares through the Employee Stock Purchase Plan, indicating continued participation in company equity programs.

Negatives

• Benjamin Halladay sold 7,046 shares of common stock.
• The sale price of $2.808 per share is relatively low, potentially reflecting current market valuation.

Future Outlook

The reported transaction, which occurred on September 17, 2025, was executed under a Rule 10b5-1 plan, indicating it was a pre-arranged sale.

Industry Context

This insider transaction is a routine event for executives managing their equity compensation and tax liabilities, common across the pharmaceutical and biotechnology industries.

Comparison to Industry Standards

• The sale of shares to satisfy tax obligations on vested restricted stock units is a standard and routine practice for executives across all industries, including the biotechnology sector, when managing equity compensation.
• The use of a Rule 10b5-1 plan for such transactions is also a common corporate governance practice, widely adopted by public company insiders to ensure compliance and mitigate concerns about insider trading.
• This filing, being a personal transaction report, does not provide specific comparable company data, projects, or results to benchmark against.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in direct insider ownership, but it is for tax purposes and not indicative of a change in management's confidence.
• Employees: The acquisition of shares through the Employee Stock Purchase Plan indicates continued employee participation in the company's equity programs.

Key Dates

Recommendation

The reported transaction is a routine insider sale by the CFO to cover tax obligations on vested restricted stock units, a common practice for executives. It was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new material non-public information. While there's a sale, the CFO also recently acquired shares through an Employee Stock Purchase Plan. This filing does not provide new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Esperion Therapeutics, ESPR, Benjamin Halladay, CFO, Insider Trading, Stock Sale, Form 4, Restricted Stock Units, Employee Stock Purchase Plan, Rule 10b5-1